Earnings Novo Nordisk’s August Reckoning: A Failed Heart Drug, a Depressed Valuation, and Earnings That Could Go Either Way
The options market is bracing for fireworks. When Novo Nordisk delivers its second-quarter results on August 5, derivatives pricing implies a roughly 8 percent swing in the Danish drugmaker’s shares...